Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Shares Outstanding (Diluted Average): 2020-2024

Historic Shares Outstanding (Diluted Average) for Spyre Therapeutics (SYRE) over the last 5 years, with Dec 2024 value amounting to $47.0 million.

  • Spyre Therapeutics' Shares Outstanding (Diluted Average) rose 18.72% to $60.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.4 million, marking a year-over-year increase of 18.72%. This contributed to the annual value of $47.0 million for FY2024, which is 581.85% up from last year.
  • According to the latest figures from FY2024, Spyre Therapeutics' Shares Outstanding (Diluted Average) is $47.0 million, which was up 581.85% from $6.9 million recorded in FY2023.
  • Spyre Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $53.4 million during FY2020, with a 5-year trough of $2.6 million in FY2021.
  • In the last 3 years, Spyre Therapeutics' Shares Outstanding (Diluted Average) had a median value of $6.9 million in 2023 and averaged $19.1 million.
  • In the last 5 years, Spyre Therapeutics' Shares Outstanding (Diluted Average) slumped by 95.07% in 2021 and then skyrocketed by 581.85% in 2024.
  • Over the past 5 years, Spyre Therapeutics' Shares Outstanding (Diluted Average) (Yearly) stood at $53.4 million in 2020, then crashed by 95.07% to $2.6 million in 2021, then climbed by 28.19% to $3.4 million in 2022, then soared by 104.59% to $6.9 million in 2023, then surged by 581.85% to $47.0 million in 2024.